Literature DB >> 10843771

Soluble CD30 serum level in HCV-positive chronic active hepatitis: A surrogate marker of disease activity?

F G Foschi1, A Gramenzi, E Castelli, C Cursaro, S Pagani, M Margotti, A D'Errico, P Andreone, G F Stefanini, M Bernardi.   

Abstract

In the present study, high levels of CD30s, a glycoprotein preferentially expressed and released by T lymphocytes producing Th(2)-type cytokines, were seen in the sera of patients with chronic hepatitis C, and a correlation with histological activity of the disease was found. CD30s levels were assayed in the sera of 29 HCV RNA-positive patients with histologically proven chronic active hepatitis and in 30 healthy blood donors. Thirteen of 29 (45%) HCV patients had CD30s serum levels above the normal range (>20 U/ml). Mean CD30s serum levels were significantly higher in HCV patients than in controls (P<0.0005). A positive correlation was found between serum CD30s levels and both the histological activity index (r=0.59, P=0.001) and ALT serum levels (r=0.5; P=0.006). The raised CD30s level found in more severe HCV liver disease indirectly suggests activation and expansion of Th(2)cells. CD30s levels could represent a useful surrogate marker of activity in chronic HCV infections. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843771     DOI: 10.1006/cyto.1999.0653

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  2 in total

1.  Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity.

Authors:  S Ajdary; F Riazi-Rad; R Jafari-Shakib; M Mohebbali
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Serum Levels of Soluble CD26, A Novel Prognostic Marker for Hepatitis E Infection.

Authors:  Alireza Rafiei; Abolghasem Ajami; Araz Mohammad Mirabi; Mohammad Jafar Saffar; Omolbanin Amjadi; Mohammad Reza Haghshenas; Farshideh Abedian; Pouya Khaje-Enayati
Journal:  Jundishapur J Microbiol       Date:  2016-02-15       Impact factor: 0.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.